ArticleCureus2025
Impact of Diabetes on Coronary Angiographic Findings in ST-Elevation Myocardial Infarction Patients: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction.Cardiovascular diabetology · 2026Trial
- Beyond borderline physiology: determinants of treatment choice and phenotypes of outcome in QFR grey-zone lesions.Cardiovascular diagnosis and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDifferences in the angiographic profile of diabetic versus non-diabetic patients with ST-elevation myocardial infarction (STEMI) may influence treatment strategies and outcomes. This study aimed to compare angiographic severity and lesion characteristics between these groups.
methodsIn this prospective comparative cross-sectional study, 150 consecutively enrolled STEMI patients (75 diabetics, 75 non-diabetics) were recruited at Hayatabad Medical Complex (HMC) over 12 months (July 2022-June 2023). Diabetes mellitus (DM) was defined according to American Diabetes Association (ADA) criteria or documented use of glucose-lowering therapy. Inclusion criteria were adults aged 30-80 years presenting with STEMI (per European Society of Cardiology (ESC) guidelines) undergoing primary or early invasive angiography. Exclusion criteria included prior percutaneous coronary intervention (PCI)/coronary artery bypass grafting (CABG), stage IV/V chronic kidney disease, or inadequate angiographic data. Two independent interventional cardiologists, blinded to diabetes status, assessed angiograms for vessel involvement, calcification, diffuse disease, and severity using the Modified Gensini Score. Interobserver agreement was evaluated (κ = 0.87). Statistical analyses included chi-square test and t-test with reporting of 95% confidence intervals (CIs), and logistic regression was used to adjust for confounders (age, hypertension, dyslipidemia, smoking). A priori sample size of 150 was determined to provide 80% power to detect a 15% difference in triple-vessel disease (TVD) prevalence between groups (α = 0.05).
resultsDiabetic patients had a higher prevalence of TVD (30, 40.0% vs. 18, 24.0%; p = 0.031, 95% CI: 1.05-3.81), diffuse disease (41, 54.7% vs. 23, 30.7%; p = 0.003, 95% CI: 1.36-4.87), and significant calcification (29, 38.7% vs. 14, 18.7%; p = 0.007, 95% CI: 1.22-4.56). The mean Gensini score was significantly higher in diabetics (42.6 ± 9.4) than non-diabetics (35.8 ± 8.7; mean difference 6.8, 95% CI: 3.4-10.2, p < 0.001). Adjusted analyses confirmed diabetes as an independent predictor of more severe and complex coronary artery disease (CAD). No significant differences were observed in culprit vessel distribution or thrombolysis in myocardial infarction (TIMI) 3 flow post PCI. At six-month follow-up, diabetics had higher rates of recurrent angina (11, 14.7% vs. 5, 6.7%), though mortality differences were not statistically significant.
conclusionSTEMI patients with diabetes demonstrate more severe, diffuse, and calcified CAD compared to non-diabetics, even after adjusting for confounders. These findings underscore the need for early, aggressive cardiovascular risk management and tailored interventional strategies in diabetic STEMI populations. Ethical approval was obtained (Ref: 757/CD/HMC/2022), and all patients provided informed consent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.